CN1535264A - 精氨酸衍生物 - Google Patents
精氨酸衍生物 Download PDFInfo
- Publication number
- CN1535264A CN1535264A CNA028100948A CN02810094A CN1535264A CN 1535264 A CN1535264 A CN 1535264A CN A028100948 A CNA028100948 A CN A028100948A CN 02810094 A CN02810094 A CN 02810094A CN 1535264 A CN1535264 A CN 1535264A
- Authority
- CN
- China
- Prior art keywords
- formulas
- naphthyl
- formula
- group
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001483 arginine derivatives Chemical class 0.000 title claims abstract description 15
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 239000001301 oxygen Substances 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 239000003446 ligand Substances 0.000 claims abstract description 4
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 3
- -1 substituted-phenyl Chemical group 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 2
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 abstract 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000002263 peptidergic effect Effects 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 239000000370 acceptor Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000009435 amidation Effects 0.000 description 6
- 238000007112 amidation reaction Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000010933 acylation Effects 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- UEOQGGDCTJBMII-UHFFFAOYSA-M C(C)OC([O-])=O.[Cl+] Chemical compound C(C)OC([O-])=O.[Cl+] UEOQGGDCTJBMII-UHFFFAOYSA-M 0.000 description 3
- UIXYJFYUNVPWIU-UHFFFAOYSA-N C(CCC)OC(OCC(C)C)=O.[Cl] Chemical compound C(CCC)OC(OCC(C)C)=O.[Cl] UIXYJFYUNVPWIU-UHFFFAOYSA-N 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001262 acyl bromides Chemical class 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 3
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 3
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229940122985 Peptide agonist Drugs 0.000 description 2
- 229940083963 Peptide antagonist Drugs 0.000 description 2
- 150000001298 alcohols Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000410 MSH receptor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102400000744 Melanotropin gamma Human genes 0.000 description 1
- 101800000520 Melanotropin gamma Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000173347 Tonsilla Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- IVIIAEVMQHEPAY-UHFFFAOYSA-N tridodecyl phosphite Chemical compound CCCCCCCCCCCCOP(OCCCCCCCCCCCC)OCCCCCCCCCCCC IVIIAEVMQHEPAY-UHFFFAOYSA-N 0.000 description 1
- GZWUQPQBOGLSIM-VOOUCTBASA-N γ msh Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C(C)C)C1=CC=C(O)C=C1 GZWUQPQBOGLSIM-VOOUCTBASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
下式表示的精氨酸衍生物或其医药上允许的盐,式中,Ar1以及Ar2可以相同或不同,表示苯基、取代苯基、萘基、取代萘基、或含有一个以上氮、氧或硫原子的杂芳香环基,Y1表示C1-5的亚烷基、C2-5的亚链烯基或单键,该C1-5亚烷基可以含有被苯基、取代苯基、萘基、取代萘基、或C1-10的酰基氨基取代的碳原子,Q表示羰基或磺酰基,Y2表示C1-5的亚烷基,该C1-5亚烷基可以含有被苯基、取代苯基、萘基、取代萘基、羟基、氨基甲酰基、单-C1-5烷基酰胺基或二-C1-5烷基酰胺基取代的碳原子。本发明提供对MC4受体具有亲和性以及特异性的肽性配体。
Description
技术领域
本发明涉及作为MC4受体配体的新型精氨酸衍生物。
背景技术
有报告说促黑激素(α、β、γ-MSH、ACTH)在脑内由其前体POMC的加工进行生物合成,并与各种生理机能相关(Nature,278,423,1979)。促黑激素通过与其特异性受体结合而表达生理机能,目前促黑激素受体(MC受体)被分类为MC1~MC5五个亚型。已确认这些受体中的MC4受体在脑内特异性地表达,并在脑内广泛分布(J.Biol.Chem.,268,15174,1993;Mol.Endocrinol.,8,1298,1994)。
最近,发现MC4受体与食欲和肥胖症有关。有报告表明在对MC4和MC3受体使用选择性肽性激动剂以及拮抗剂的动物实验中,对禁食小鼠和各种肥胖模型表现出强力的抑制食欲作用(Nature,385,165,1997)。
另外,在MC4受体KO小鼠中发现明显的体重增加、血中胰岛素量、葡萄糖量增加(Cell,88,131,1997),确认MC4受体对摄食行为以及肥胖具有抑制作用。
另外,发现MC4受体在脑内除了分布在与摄食行为密切相关的丘脑下部之外,在海马、扁桃体等边缘区以及作为血清素神经的起始核的缝线核等处也广泛分布(Mol.Endocrinol.,8,1298,1994)。另外,发现ACTH以及α-MSH在动物实验中对体温调节(Brain Res.,18,473,1987)、血压(Am.J.Physiol.,257,R681,1989)、神经内分泌系统(Life Sci.,25,1791,1979)、学习/记忆(Neurosci.Biobehav.Rev.,4,9,1980)以及觉醒(Neurosci.Biobehav.Rev.,4,9.1980)有作用,并且有报告表明可以引发焦虑症状、丘脑下部-下垂体-肾上腺系统的活化(Pharmacol.Biochem.Behav.,36,631,1990;Peptides,17,171,1996;ibid,11,647,1990;ibid,11,915,1990;Pharmacol.Biochem.Behav.,12,711,1980)。但是,ACTH以及α-MSH是亚型非特异性的激动剂,但促黑激素受体亚型与这些生理机能的关系还不明确。
关于MC4受体,报道了肽性激动剂和拮抗剂(Nature,385,165,1997)。但是,它们与MC3受体也具有亲和性,不能作为对MC4受体具有选择性的配体使用。另外,对MC4受体具有特异性的配体则完全没有相关报告。所以,MC受体中,对在脑内特异表达的、在脑内广泛分布的MC4受体的相关生理机能也还不明确。
本发明的目的是提供对MC4受体具有亲和性以及特异性的作为医药品有用的肽性配体。
发明内容
本发明者通过对精氨酸衍生物进行深入的研究,结果发现了作为与MC4受体具有亲和性的配体的精氨酸衍生物,从而完成了本发明。
以下说明本发明。
本发明为下式[1]表示的精氨酸衍生物或其医药上允许的盐。
式中,Ar1以及Ar2可以相同或不同,表示苯基、取代苯基、萘基、取代萘基、或含有一个或一个以上氮、氧或硫原子的杂芳香环基,Y1表示C1-5的亚烷基、C2-5的亚链烯基或单键,该C1-5亚烷基可以含有被苯基、取代苯基、萘基、取代萘基、或C1-10酰基氨基取代的碳原子,Q表示羰基或磺酰基,Y2表示C1-5的亚烷基,该C1-5亚烷基可以含有被苯基、取代苯基、萘基、取代萘基、羟基、氨基甲酰基、单-C1-5烷基酰胺基或二-C1-5烷基酰胺基取代的碳原子。另外,本发明的精氨酸衍生物中如果存在立体异构体的话,这些立体异构体也包括在本发明中。
在本发明中,取代苯基是指被从C1-5烷基、C1-5烷氧基、芳烷氧基、羟基、卤素原子、硝基、氨基、单-C1-5烷基氨基、二-C1-5烷基氨基、三氟甲基以及苯基中任意选择的1~3个基团取代的苯基,例如2-甲基苯基、3-甲基苯基、4-甲基苯基、2-乙基苯基、3-乙基苯基、4-乙基苯基、2-丙基苯基、3-丙基苯基、4-丙基苯基、2-环戊基苯基、2-甲氧基苯基、3-甲氧基苯基、4-甲氧基苯基、4-乙氧基苯基、4-异丙氧基苯基、4-苄氧基苯基、4-羟基苯基、2-氟苯基、3-氟苯基、4-氟苯基、2-氯苯基、3-氯苯基、4-氯苯基、2-溴苯基、3-溴苯基、4-溴苯基、4-硝基苯基、4-三氟甲基苯基、4-联苯基等。
取代萘基是指被从C1-5烷基、C1-5烷氧基、芳烷氧基、卤素原子、硝基、氨基、单-C1-5烷基氨基、二-C1-5烷基氨基、三氟甲基以及苯基中任意选择的1~3个基团取代的萘基,例如5-二甲基氨基萘基等。
含有一个以上氮、氧或硫原子的杂芳香环基,是指含有一个以上氮、氧或硫原子的单环或2环芳香族环基,例如2-吡啶基、3-吡啶基、4-吡啶基、3-吲哚基、3-苯并噻嗯基或4-咪唑基等。
C1-10的酰基氨基是指碳原子数1至10的脂肪族酰基或芳香族酰基取代的氨基,例如甲酰基氨基、乙酰基氨基、丙酰基氨基、丁酰基氨基、异丁酰基氨基、戊酰基氨基、异戊酰基氨基、三甲基乙酰基氨基、环己基氨基、苄氧基羰基氨基、叔丁氧基羰基氨基等。
C1-5的烷基是指碳原子数1至5个的直链状、支链状或环状的烷基,例如甲基、乙基、丙基、异丙基、环丙基、丁基、异丁基、环丁基、环丙基甲基、戊基、异戊基、环戊基、环丁基甲基、1-乙基丙基等。
C1-5的烷氧基是指碳原子数1至5个的直链状、支链状或环状烷氧基,例如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、环丙基甲氧基、戊氧基、异戊氧基等。
单-C1-5的烷基氨基或二-C1-5的烷基氨基,是指上述C1-5的烷基取代的氨基,例如甲基氨基、乙基氨基、丙基氨基、二甲基氨基、二乙基氨基、二丙基氨基等。
卤素原子是指氟原子、氯原子、溴原子或碘原子。
另外,医药学上允许的盐,是指无机酸或有机酸的盐。其中例如乙酸盐、丙酸盐、丁酸盐、甲酸盐、三氟乙酸盐、马来酸盐、酒石酸盐、柠檬酸盐、硬脂酸盐、琥珀酸盐、乙基琥珀酸盐、乳糖醛酸盐、葡糖酸盐、葡庚糖酸盐、苯甲酸盐、甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、对甲苯磺酸盐、月桂基硫酸盐、苹果酸盐、天冬氨酸盐、谷氨酸盐、己二酸盐、与半胱氨酸形成的盐、与N-乙酰基半胱氨酸形成的盐、盐酸盐、氢溴酸盐、磷酸盐、氢碘酸盐、烟酸盐、草酸盐、苦味酸盐、硫氰酸盐、十一烷酸盐、与丙烯酸聚合物形成的盐、与羧基乙烯基聚合物形成的盐等。
本发明优选的化合物是式[1]中Ar1以及Ar2可以相同或不同,表示苯基、萘基或3-苯并噻嗯基,Y1表示C1-2的亚烷基、或被1个乙酰基氨基取代的C1-2亚烷基,Q表示羰基或磺酰基,Y2表示C1-2的亚烷基或被1个氨基甲酰基取代的C1-2亚烷基的精氨酸衍生物或其医药学允许的盐。更优选下面所示的的化合物a~n或其医药上允许的盐。
a.N2-[N-乙酰基-3-(2-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
b.N2-[N-乙酰基-3-(2-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
c.N2-[N-乙酰基-3-(2-萘基)-D-丙氨酰基]-N-[2-(2-萘基)乙基]-L-精氨酸酰胺
d.N2-[N-乙酰基-3-(1-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
e.N2-[N-乙酰基-3-(1-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
f.N2-[N-乙酰基-3-(1-萘基)-D-丙氨酰基]-L-精氨酰基-3-(1-萘基)-L-丙氨酸酰胺
g.N2-[N-乙酰基-D-苯基丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
h.N2-[N-乙酰基-D-苯基丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
i.N2-[N-乙酰基-D-苯基丙氨酰基]-N-[2-(2-萘基)乙基]-L-精氨酸酰胺
j.N2-[3-(2-萘基)丙酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
k.N2-[3-(1-萘基)丙酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
l.N2-[N-乙酰基-3-(3-苯并噻嗯基)-L-丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
m.N2-[N-乙酰基-3-(3-苯并噻嗯基)-L-丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
n.N2-[1-萘磺酰基]-L-精氨酰基-3-(3-苯并噻嗯基)-D-丙氨酸酰胺
式[1]化合物可以按照以下的常用制造方法制备。(在下面的反应式中,Ar1、Ar2、Y1、Y2、Q与上述含义相同,X表示羟基、氯原子、溴原子或碘原子,P1表示叔丁氧羰基、苄氧羰基等常用的氨基保护基,P2、P3表示叔丁氧羰基、苄氧羰基、硝基、对甲苯磺酰基或2,2,5,7,8-五甲基苯并二氢吡喃-6-磺酰基等常用的胍基保护基。)
[常用的制造方法]
[步骤1]
化合物(1)和化合物(2)在碱存在或不存在的条件下,在惰性溶剂中缩合可以转化成化合物(3)。
此处所说的碱是指例如三乙胺、二异丙基乙胺、吡啶、N-甲基吗啉等有机胺类,碳酸钾、碳酸氢钠等无机碱类。缩合是指例如经由酰氯或酰溴等酰卤的酰胺化,经由使用氯碳酸乙酯、氯碳酸异丁酯等混合酸酐的酰胺化,或使用1-(3,3-二甲基氨基丙基)-3-乙基碳化二亚胺、1,3-二环己基碳化二亚胺、二苯基磷酰基迭氮、氰基磷酸二乙酯或羰基咪唑等缩合剂的酰胺化。惰性溶剂例如甲醇、乙醇等醇类,二乙醚、四氢呋喃等醚类,甲苯、苯等烃类,氯仿、二氯甲烷等卤代烃类溶剂,二甲基甲酰胺、乙腈、水或它们的混合溶剂等。
[步骤2]
在酸的存在下或不存在下,在惰性溶剂中对化合物(3)进行脱保护,可以得到化合物(4)。有关化合物(3)的脱保护,可以利用记载在“有机合成中的保护基”(Protective Groups in Organic Synthesis,Theodora W.Greene and Peter G.M.Wuts等著)中的方法进行。
[步骤3]
化合物(4)和化合物(5)在碱的存在下或不存在下,通过在惰性溶剂中缩合,可以转化成化合物(6)。此时在Y1含有被保护的氨基时,脱保护后,在碱的存在或不存在下,在惰性溶剂中可以进行氨基的酰基化。
此处使用的碱,例如有三乙胺、二异丙基乙胺、吡啶或N-甲基吗啉等有机胺类,碳酸钾或碳酸氢钠等无机碱类。缩合是指例如经由酰氯或酰溴等酰卤的酰胺化,经由使用氯碳酸乙酯、氯碳酸异丁酯等混合酸酐的酰胺化,或使用1-(3,3-二甲基氨基丙基)-3-乙基碳化二亚胺、1,3-二环己基碳化二亚胺、二苯基磷酰基迭氮、氰基磷酸二乙酯或羰基咪唑等缩合剂的酰胺化。惰性溶剂例如甲醇、乙醇等醇类,二乙醚、四氢呋喃等醚类,甲苯、苯等烃类,氯仿、二氯甲烷等卤代烃类溶剂,二甲基甲酰胺、乙腈、水或它们的混合溶剂。被保护的氨基是指记载在“有机合成中的保护基”(Protective Groups inOrganic Synthesis,Theodora W.Greene and Peter G.M.Wuts等著)中的保护氨基,例如叔丁氧基羰基氨基或苄氧基羰基氨基等。脱保护是指按照“有机合成中的保护基”(Protective Groups in Organic Synthesis,Theodora W.Greene and Peter G.M.Wuts等著)中记载的方法进行氨基的脱保护。酰基化是指经由酰氯或酰溴等酰卤的酰基化,使用乙酸酐等酸酐的酰基化,经由使用氯碳酸乙酯、氯碳酸异丁酯等混合酸酐的酰基化,或使用1-(3,3-二甲基氨基丙基)-3-乙基碳化二亚胺、1,3-二环己基碳化二亚胺、二苯基磷酰基迭氮、氰基磷酸二乙酯或羰基咪唑等缩合剂的酰基化。
[步骤4]
在酸存在下或不存在下,在惰性溶剂中进行胍基的脱保护,可以得到本发明的化合物(6)。
此处化合物胍基的脱保护,可以使用“有机合成中的保护基”(Protective Groups in Organic Synthesis,Theodora W.Greene andPeter G.M.Wuts等著)中记载的方法进行。
将本发明的化合物作为医药或MC4受体配体使用时的给药量,在成人治疗时优选1日1~2000mg,每日一次或分数次给药。给药量根据用途、患者的年龄、体重以及症状等不同可以进行适当的增减。
本发明的化合物可以口服或非口服给药。给药剂型如片剂、胶囊剂、颗粒剂、散剂、粉剂、糖衣剂、软膏剂、霜剂、乳剂、悬浊剂、栓剂、注射剂、经鼻给药剂等,这些制剂都可以按照常用的制剂方法(例如第14版修订日本药局方中规定的方法)制备。根据患者的症状、年龄以及治疗目的不同可以适当的选择给药剂型。在制备各种剂型的制剂时,可以使用常用的的赋形剂(例如结晶纤维素、淀粉、乳糖、甘露糖醇等)、粘合剂(例如羟丙基纤维素、聚乙烯吡咯烷酮等)、润滑剂(例如硬脂酸镁、滑石等)、崩解剂(例如羧甲基纤维素钙等)等。
具体实施方式
下面通过实施例更详细的说明本发明,但本发明并不局限于这些实施例。(在下面的式中,Boc表示叔丁基羰基、Z表示苄氧羰基、Ac表示乙酰基。)
实施例1[表1中的化合物224的合成]
(1)将中间体1(2.16g)、中间体2(1.00g)、1-羟基苯并三唑1水合物(0.92g)以及N-甲基吗啉(0.42g)溶解在二甲基甲酰胺(20ml)中,冰浴下加入1-(3,3-二甲基氨基丙基)-3-乙基碳化二亚胺盐酸盐(0.96g),缓慢升温至室温,搅拌3日。将反应溶液注入乙酸乙酯和水的混合溶剂中,分液后将有机层依次用5%硫酸氢钾水溶液、饱和碳酸氢钠水溶液和饱和氯化钠水溶液洗涤,用无水硫酸钠干燥后,滤除干燥剂,减压浓缩。将得到的结晶用乙酸乙酯重结晶,得到中间体3(2.27g)。
(2)将(1)得到的中间体(3)(1.50g)溶解在二氯甲烷(15ml)中,加入三氟乙酸(15ml),在室温下搅拌2小时。将反应液减压浓缩,注入饱和碳酸氢钠水溶液,用氯仿萃取。将有机层用无水硫酸钠干燥后,滤除干燥剂,减压下浓缩,得到粗的中间体4。该中间体4不用纯化可直接用于之后的反应。
(3)将(2)得到的中间体(4)(0.42g)、中间体5(0.24g)以及1-羟基苯并三唑1水合物(0.16g)溶解在二甲基甲酰胺(15ml)中,在冰冷却条件下加入1-(3,3-二甲基氨基丙基)-3-乙基碳化二亚胺盐酸盐(0.16g),缓慢升温至室温,搅拌一夜。将反应溶液注入乙酸乙酯和水的混合溶剂中,分液后将有机层依次用5%硫酸氢钾水溶液、饱和碳酸氢钠水溶液和饱和氯化钠水溶液洗涤,用无水硫酸钠干燥后,滤除干燥剂,减压浓缩。残渣在乙酸乙酯中结晶化,得到中间体6(0.43g)。
(4)将(3)得到的中间体6(0.40g)溶解在二氯甲烷(5ml)中,加入三氟乙酸(5ml),在室温下搅拌2小时。将反应液减压浓缩,注入饱和碳酸氢钠水溶液,用氯仿萃取。将有机层用无水硫酸钠干燥后,滤除干燥剂,减压下浓缩。将残渣溶解在二氯甲烷(3ml)中,加入乙酸酐(48mg)以及吡啶(37mg)的二氯甲烷溶液(1ml),在室温下搅拌2小时。将反应溶液减压下浓缩,注入乙酸乙酯,依次用水、5%硫酸氢钾水溶液、饱和碳酸氢钠水溶液以及饱和氯化钠水溶液洗涤,用无水硫酸钠干燥后,滤除干燥剂后减压浓缩。将残渣在乙酸乙酯中结晶化,得到中间体7(0.28g)。
(5)将(4)得到的中间体7(0.28g)溶解在甲醇(10ml)中,加入20%氢氧化钯-活性炭(100mg),在氢气气氛下搅拌2日。将反应溶液用硅藻土过滤除去固形物,减压下浓缩。将残渣溶解在甲醇(5ml)中,加入4M氯化氢-乙酸乙酯溶液(0.10ml)减压下浓缩,得到在乙酸乙酯中固化的化合物224的盐酸盐(0.18g)。
本化合物以及用同样方法得到的化合物的结构以及物性数据如表1所示。
表1
化合物序号 Ar1-Y1 Q Y2-Ar2 (M+1)+*1
001 式(1) CO 式(a) 501.3
002 式(1) CO 式(b) 501.3
003 式(1) CO 式(c) 515.3
004 式(1) CO 式(d) 515.3
005 式(1) CO 式(e) 551.3
006 式(1) CO 式(f) 551.3
007 式(1) CO 式(g) 551.3
008 式(1) CO 式(h) 551.3
009 式(1) CO 式(i) 502.3
010 式(1) CO 式(j) 502.3
011 式(1) CO 式(k) 491.3
012 式(1) CO 式(l) 491.3
013 式(2) CO 式(a) 501.3
014 式(2) CO 式(b) 501.3
015 式(2) CO 式(c) 515.3
016 式(2) CO 式(d) 515.3
017 式(2) CO 式(e) 551.3
018 式(2) CO 式(f) 551.3
019 式(2) CO 式(g) 551.3
020 式(2) CO 式(h) 551.3
021 式(2) CO 式(i) 502.3
022 式(2) CO 式(j) 502.3
023 式(2) CO 式(k) 491.3
024 式(2) CO 式(l) 491.3
025 式(3) CO 式(a) 503.3
026 式(3) CO 式(b) 503.3
027 式(3) CO 式(c) 517.3
028 式(3) CO 式(d) 517.3
029 式(3) CO 式(e) 553.3
030 式(3) CO 式(f) 553.3
031 式(3) CO 式(g) 553.3
032 式(3) CO 式(h) 553.3
033 式(3) CO 式(i) 504.3
034 式(3) CO 式(j) 504.3
035 式(3) CO 式(k) 493.3
036 式(3) CO 式(l) 493.3
037 式(4) CO 式(a) 629.4
038 式(4) CO 式(b) 629.4
039 式(4) CO 式(c) 643.4
040 式(4) CO 式(d) 643.4
041 式(4) CO 式(e) 679.3
042 式(4) CO 式(f) 679.3
043 式(4) CO 式(g) 679.3
044 式(4) CO 式(h) 679.3
045 式(4) CO 式(i) 630.4
046 式(4) CO 式(j) 630.4
047 式(4) CO 式(k) 619.4
048 式(4) CO 式(l) 619.4
049 式(5) CO 式(a) 629.4
050 式(5) CO 式(b) 629.4
051 式(5) CO 式(c) 643.4
052 式(5) CO 式(d) 643.4
053 式(5) CO 式(e) 679.3
054 式(5) CO 式(f) 679.3
055 式(5) CO 式(g) 679.3
056 式(5) CO 式(h) 679.3
057 式(5) CO 式(i) 630.4
058 式(5) CO 式(j) 630.4
059 式(5) CO 式(k) 619.4
060 式(5) CO 式(l) 619.4
061 式(6) CO 式(a) 629.4
062 式(6) CO 式(b) 629.4
063 式(6) CO 式(c) 643.4
064 式(6) CO 式(d) 643.4
065 式(6) CO 式(e) 679.3
066 式(6) CO 式(f) 679.3
067 式(6) CO 式(g) 679.3
068 式(6) CO 式(h) 679.3
069 式(6) CO 式(i) 630.4
070 式(6) CO 式(j) 630.4
071 式(6) CO 式(k) 619.4
072 式(6) CO 式(l) 619.4
073 式(7) SO2 式(a) 511.2
074 式(7) SO2 式(b) 511.2
075 式(7) SO2 式(c) 525.3
076 式(7) SO2 式(d) 525.3
077 式(7) SO2 式(e) 561.3
078 式(7) SO2 式(f) 561.3
079 式(7) SO2 式(g) 561.3
080 式(7) SO2 式(h) 561.3
081 式(7) SO2 式(i) 512.2
082 式(7) SO2 式(j) 512.2
083 式(7) SO2 式(k) 501.2
084 式(7) SO2 式(l) 501.2
085 式(8) SO2 式(a) 554.3
086 式(8) SO2 式(b) 554.3
087 式(8) SO2 式(c) 568.3
088 式(8) SO2 式(d) 568.3
089 式(8) SO2 式(e) 604.3
090 式(8) SO2 式(f) 604.3
091 式(8) SO2 式(g) 604.3
092 式(8) SO2 式(h) 604.3
093 式(8) SO2 式(i) 555.3
094 式(8) SO2 式(j) 555.3
095 式(8) SO2 式(k) 544.3
096 式(8) SO2 式(l) 544.3
097 式(1) CO 式(m) 487.2
098 式(1) CO 式(n) 487.2
099 式(1) CO 式(o) 502.3
100 式(1) CO 式(p) 502.3
101 式(1) CO 式(q) 502.3
102 式(1) CO 式(r) 557.2
103 式(1) CO 式(s) 577.2
104 式(1) CO 式(t) 577.2
105 式(2) CO 式(m) 487.2
106 式(2) CO 式(n) 487.3
107 式(2) CO 式(o) 502.3
108 式(2) CO 式(p) 502.3
109 式(2) CO 式(q) 502.3
110 式(2) CO 式(r) 557.2
111 式(2) CO 式(s) 577.2
112 式(2) CO 式(t) 577.2
113 式(3) CO 式(m) 489.3
114 式(3) CO 式(n) 489.3
115 式(3) CO 式(o) 504.3
116 式(3) CO 式(p) 504.3
117 式(3) CO 式(q) 504.3
118 式(3) CO 式(r) 559.2
119 式(3) CO 式(s) 579.3
120 式(3) CO 式(t) 579.3
121 式(4) CO 式(m) 615.3
122 式(4) CO 式(n) 615.3
123 式(4) CO 式(o) 630.4
124 式(4) CO 式(p) 630.3
125 式(4) CO 式(q) 630.3
126 式(4) CO 式(r) 685.3
127 式(4) CO 式(s) 705.3
128 式(4) CO 式(t) 705.3
129 式(5) CO 式(m) 615.3
130 式(5) CO 式(n) 615.3
131 式(5) CO 式(o) 630.3
132 式(5) CO 式(p) 630.3
133 式(5) CO 式(q) 630.4
134 式(5) CO 式(r) 685.2
135 式(5) CO 式(s) 705.3
136 式(5) CO 式(t) 705.3
137 式(6) CO 式(m) 615.3
138 式(6) CO 式(n) 615.3
139 式(6) CO 式(o) 630.3
140 式(6) CO 式(p) 630.3
141 式(6) CO 式(q) 630.3
142 式(6) CO 式(r) 685.2
143 式(6) CO 式(s) 705.3
144 式(6) CO 式(t) 705.3
145 式(7) SO2 式(m) 497.2
146 式(7) SO2 式(n) 497.2
147 式(7) SO2 式(p) 512.2
148 式(7) SO2 式(r) 567.1
149 式(7) SO2 式(s) 587.2
150 式(7) SO2 式(t) 587.2
151 式(8) SO2 式(m) 540.3
152 式(8) SO2 式(n) 540.3
153 式(8) SO2 式(p) 555.2
154 式(8) SO2 式(r) 610.2
155 式(8) SO2 式(s) 630.3
156 式(8) SO2 式(t) 630.3
157 式(9) CO 式(a) 510.3
158 式(9) CO 式(b) 510.3
159 式(9) CO 式(c) 524.3
160 式(9) CO 式(d) 524.3
161 式(9) CO 式(e) 560.3
162 式(9) CO 式(f) 560.3
163 式(9) CO 式(g) 560.3
164 式(9) CO 式(h) 560.3
165 式(9) CO 式(i) 511.3
166 式(9) CO 式(j) 511.3
167 式(9) CO 式(k) 500.3
168 式(9) CO 式(l) 500.3
169 式(10) CO 式(a) 510.3
170 式(10) CO 式(b) 510.3
171 式(10) CO 式(c) 524.3
172 式(10) CO 式(d) 524.3
173 式(10) CO 式(e) 560.3
174 式(10) CO 式(f) 560.3
175 式(10) CO 式(g) 560.3
176 式(10) CO 式(h) 560.3
177 式(10) CO 式(i) 511.3
178 式(10) CO 式(j) 511.3
179 式(10) CO 式(k) 500.3
180 式(10) CO 式(l) 500.3
181 式(11) CO 式(a) 524.3
182 式(11) CO 式(b) 524.3
183 式(11) CO 式(c) 538.3
184 式(11) CO 式(d) 538.3
185 式(11) CO 式(e) 574.3
186 式(11) CO 式(f) 574.3
187 式(11) CO 式(g) 574.3
188 式(11) CO 式(h) 574.3
189 式(11) CO 式(i) 525.3
190 式(11) CO 式(j) 525.3
191 式(11) CO 式(k) 514.3
192 式(11) CO 式(l) 514.3
193 式(12) CO 式(a) 524.3
194 式(12) CO 式(b) 524.3
195 式(12) CO 式(c) 538.3
196 式(12) CO 式(d) 538.3
197 式(12) CO 式(e) 574.3
198 式(12) CO 式(f) 574.3
199 式(12) CO 式(g) 574.3
200 式(12) CO 式(h) 574.3
201 式(12) CO 式(i) 525.3
202 式(12) CO 式(j) 525.3
203 式(12) CO 式(k) 514.3
204 式(12) CO 式(l) 514.3
205 式(13) CO 式(a) 560.3
206 式(13) CO 式(b) 560.3
207 式(13) CO 式(c) 574.3
208 式(13) CO 式(d) 574.3
209 式(13) CO 式(e) 610.3
210 式(13) CO 式(f) 610.3
211 式(13) CO 式(g) 610.3
212 式(13) CO 式(h) 610.3
213 式(13) CO 式(i) 561.3
214 式(13) CO 式(j) 561.3
215 式(13) CO 式(k) 550.3
216 式(13) CO 式(l) 550.3
217 式(14) CO 式(a) 560.3
218 式(14) CO 式(b) 560.3
219 式(14) CO 式(c) 574.3
220 式(14) CO 式(d) 574.3
221 式(14) CO 式(e) 610.3
222 式(14) CO 式(f) 610.3
223 式(14) CO 式(g) 610.3
224 式(14) CO 式(h) 610.3
225 式(14) CO 式(i) 561.3
226 式(14) CO 式(j) 561.3
227 式(14) CO 式(k) 550.3
228 式(14) CO 式(l) 550.3
229 式(15) CO 式(a) 560.3
230 式(15) CO 式(b) 560.3
231 式(15) CO 式(c) 574.3
232 式(15) CO 式(d) 574.3
233 式(15) CO 式(e) 610.3
234 式(15) CO 式(f) 610.3
235 式(15) CO 式(g) 610.3
236 式(15) CO 式(h) 610.3
237 式(15) CO 式(i) 561.3
238 式(15) CO 式(j) 561.3
239 式(15) CO 式(k) 550.3
240 式(15) CO 式(l) 550.3
241 式(16) CO 式(a) 560.3
242 式(16) CO 式(b) 560.3
243 式(16) CO 式(c) 574.3
244 式(16) CO 式(d) 574.3
245 式(16) CO 式(e) 610.3
246 式(16) CO 式(f) 610.3
247 式(16) CO 式(g) 610.3
248 式(16) CO 式(h) 610.3
249 式(16) CO 式(i) 561.3
250 式(16) CO 式(j) 561.3
251 式(16) CO 式(k) 550.3
252 式(16) CO 式(l) 550.3
253 式(9) CO 式(m) 496.3
254 式(9) CO 式(n) 496.3
255 式(9) CO 式(o) 511.3
256 式(9) CO 式(p) 511.3
257 式(9) CO 式(q) 511.3
258 式(9) CO 式(r) 566.2
259 式(9) CO 式(s) 586.3
260 式(9) CO 式(t) 586.3
261 式(10) CO 式(m) 496.3
262 式(10) CO 式(n) 496.3
263 式(10) CO 式(o) 511.3
264 式(10) CO 式(p) 511.3
265 式(10) CO 式(q) 511.3
266 式(10) CO 式(r) 566.2
267 式(10) CO 式(s) 586.3
268 式(10) CO 式(t) 586.3
269 式(11) CO 式(m) 510.3
270 式(11) CO 式(n) 510.3
271 式(11) CO 式(o) 525.3
272 式(11) CO 式(p) 525.3
273 式(11) CO 式(q) 525.3
274 式(11) CO 式(r) 580.2
275 式(11) CO 式(s) 600.3
276 式(11) CO 式(t) 600.3
277 式(12) CO 式(m) 510.3
278 式(12) CO 式(n) 510.3
279 式(12) CO 式(o) 525.3
280 式(12) CO 式(p) 525.3
281 式(12) CO 式(q) 525.3
282 式(12) CO 式(r) 580.2
283 式(12) CO 式(s) 600.3
284 式(12) CO 式(t) 600.3
285 式(13) CO 式(m) 546.3
286 式(13) CO 式(n) 546.3
287 式(13) CO 式(o) 561.3
288 式(13) CO 式(p) 561.3
289 式(13) CO 式(q) 561.3
290 式(13) CO 式(r) 616.3
291 式(13) CO 式(s) 636.4
292 式(13) CO 式(t) 636.4
293 式(14) CO 式(m) 546.3
294 式(14) CO 式(n) 546.3
295 式(14) CO 式(o) 561.3
296 式(14) CO 式(p) 561.3
297 式(14) CO 式(q) 561.3
298 式(14) CO 式(r) 616.3
299 式(14) CO 式(s) 616.4
300 式(14) CO 式(t) 636.4
301 式(15) CO 式(m) 546.3
302 式(15) CO 式(n) 546.3
303 式(15) CO 式(o) 561.2
304 式(15) CO 式(p) 561.3
305 式(15) CO 式(q) 561.3
306 式(15) CO 式(r) 616.3
307 式(15) CO 式(s) 636.4
308 式(15) CO 式(t) 636.4
309 式(16) CO 式(m) 546.3
310 式(16) CO 式(n) 546.3
311 式(16) CO 式(o) 561.3
312 式(16) CO 式(p) 561.3
313 式(16) CO 式(q) 561.3
314 式(16) CO 式(r) 616.3
315 式(16) CO 式(s) 636.4
316 式(16) CO 式(t) 636.4
317 式(17) CO 式(a) 511.3
318 式(17) CO 式(b) 511.3
319 式(17) CO 式(c) 525.3
320 式(17) CO 式(d) 525.3
321 式(17) CO 式(e) 561.3
322 式(17) CO 式(f) 561.3
323 式(17) CO 式(g) 561.3
324 式(17) CO 式(h) 561.3
325 式(17) CO 式(i) 512.3
326 式(17) CO 式(j) 512.3
327 式(17) CO 式(k) 501.3
328 式(17) CO 式(l) 501.3
329 式(18) CO 式(a) 511.3
330 式(18) CO 式(b) 511.3
331 式(18) CO 式(c) 525.3
332 式(18) CO 式(d) 525.3
333 式(18) CO 式(e) 561.3
334 式(18) CO 式(f) 561.3
335 式(18) CO 式(g) 561.3
336 式(18) CO 式(h) 561.3
337 式(18) CO 式(i) 512.3
338 式(18) CO 式(j) 512.3
339 式(18) CO 式(k) 501.3
340 式(18) CO 式(l) 501.3
341 式(19) CO 式(a) 500.3
342 式(19) CO 式(b) 500.3
343 式(19) CO 式(c) 514.3
344 式(19) CO 式(d) 514.3
345 式(19) CO 式(e) 550.3
346 式(19) CO 式(f) 550.3
347 式(19) CO 式(g) 550.3
348 式(19) CO 式(h) 550.3
349 式(19) CO 式(i) 501.3
350 式(19) CO 式(j) 501.3
351 式(19) CO 式(k) 490.3
352 式(19) CO 式(l) 490.3
353 式(20) CO 式(a) 500.3
354 式(20) CO 式(b) 500.3
355 式(20) CO 式(c) 514.3
356 式(20) CO 式(d) 514.3
357 式(20) CO 式(e) 550.3
358 式(20) CO 式(f) 550.3
359 式(20) CO 式(g) 550.3
360 式(20) CO 式(h) 550.3
361 式(20) CO 式(i) 501.3
362 式(20) CO 式(j) 501.3
363 式(20) CO 式(k) 490.3
364 式(20) CO 式(l) 490.3
365 式(21) CO 式(a) 496.3
366 式(21) CO 式(b) 496.3
367 式(21) CO 式(c) 510.3
368 式(21) CO 式(d) 510.3
369 式(21) CO 式(e) 546.3
370 式(21) CO 式(f) 546.3
371 式(21) CO 式(g) 546.3
372 式(21) CO 式(h) 546.3
373 式(21) CO 式(i) 497.3
374 式(21) CO 式(j) 497.3
375 式(21) CO 式(k) 486.3
376 式(21) CO 式(l) 486.3
377 式(22) CO 式(a) 496.3
378 式(22) CO 式(b) 496.3
379 式(22) CO 式(c) 510.3
380 式(22) CO 式(d) 510.3
381 式(22) CO 式(e) 546.3
382 式(22) CO 式(f) 546.3
383 式(22) CO 式(g) 546.3
384 式(22) CO 式(h) 546.3
385 式(22) CO 式(i) 497.3
386 式(22) CO 式(j) 497.3
387 式(22) CO 式(k) 486.3
388 式(22) CO 式(l) 486.3
389 式(23) CO 式(a) 511.3
390 式(23) CO 式(b) 511.3
391 式(23) CO 式(c) 525.3
392 式(23) CO 式(d) 525.3
393 式(23) CO 式(e) 561.3
394 式(23) CO 式(f) 561.3
395 式(23) CO 式(g) 561.3
396 式(23) CO 式(h) 561.3
397 式(23) CO 式(i) 512.3
398 式(23) CO 式(j) 512.3
399 式(23) CO 式(k) 501.3
400 式(23) CO 式(l) 501.3
401 式(24) CO 式(a) 511.3
402 式(24) CO 式(b) 511.3
403 式(24) CO 式(c) 525.3
404 式(24) CO 式(d) 525.3
405 式(24) CO 式(e) 561.3
406 式(24) CO 式(f) 561.3
407 式(24) CO 式(g) 561.3
408 式(24) CO 式(h) 561.3
409 式(24) CO 式(i) 512.3
410 式(24) CO 式(j) 512.3
411 式(24) CO 式(k) 501.3
412 式(24) CO 式(l) 501.3
413 式(17) CO 式(m) 497.3
414 式(17) CO 式(n) 497.3
415 式(17) CO 式(o) 512.3
416 式(17) CO 式(p) 512.3
417 式(17) CO 式(q) 512.3
418 式(17) CO 式(r) 567.2
419 式(17) CO 式(s) 587.3
420 式(17) CO 式(t) 587.3
421 式(18) CO 式(m) 497.3
422 式(18) CO 式(n) 497.3
423 式(18) CO 式(o) 512.3
424 式(18) CO 式(p) 512.3
425 式(18) CO 式(q) 512.3
426 式(18) CO 式(r) 567.2
427 式(18) CO 式(s) 587.3
428 式(18) CO 式(t) 587.3
429 式(19) CO 式(m) 486.3
430 式(19) CO 式(n) 486.3
431 式(19) CO 式(o) 501.3
432 式(19) CO 式(p) 501.3
433 式(19) CO 式(q) 501.3
434 式(19) CO 式(r) 556.2
435 式(19) CO 式(s) 576.3
436 式(19) CO 式(t) 576.3
437 式(20) CO 式(m) 486.3
438 式(20) CO 式(n) 486.3
439 式(20) CO 式(o) 501.3
440 式(20) CO 式(p) 501.3
441 式(20) CO 式(q) 501.3
442 式(20) CO 式(r) 556.2
443 式(20) CO 式(s) 576.3
444 式(20) CO 式(t) 576.3
445 式(21) CO 式(m) 482.2
446 式(21) CO 式(n) 482.2
447 式(21) CO 式(o) 497.3
448 式(21) CO 式(p) 497.3
449 式(21) CO 式(q) 497.3
450 式(21) CO 式(r) 552.2
451 式(21) CO 式(s) 572.3
452 式(21) CO 式(t) 572.3
453 式(22) CO 式(m) 482.3
454 式(22) CO 式(n) 482.3
455 式(22) CO 式(o) 497.3
456 式(22) CO 式(p) 497.3
457 式(22) CO 式(q) 497.3
458 式(22) CO 式(r) 552.2
459 式(22) CO 式(s) 572.3
460 式(22) CO 式(t) 572.3
461 式(23) CO 式(m) 497.3
462 式(23) CO 式(n) 497.3
463 式(23) CO 式(o) 512.3
464 式(23) CO 式(p) 512.3
465 式(23) CO 式(q) 512.3
466 式(23) CO 式(r) 567.2
467 式(23) CO 式(s) 587.3
468 式(23) CO 式(t) 587.3
469 式(24) CO 式(m) 497.3
470 式(24) CO 式(n) 497.3
471 式(24) CO 式(o) 512.3
472 式(24) CO 式(p) 512.3
473 式(24) CO 式(q) 512.4
474 式(24) CO 式(r) 567.2
475 式(24) CO 式(s) 587.3
476 式(24) CO 式(t) 587.3
477 式(25) CO 式(a) 511.3
478 式(25) CO 式(b) 511.3
479 式(25) CO 式(c) 525.3
480 式(25) CO 式(d) 525.3
481 式(25) CO 式(e) 561.3
482 式(25) CO 式(f) 561.3
483 式(25) CO 式(g) 561.3
484 式(25) CO 式(h) 561.3
485 式(25) CO 式(i) 512.3
486 式(25) CO 式(j) 512.3
487 式(25) CO 式(k) 501.3
488 式(25) CO 式(l) 501.3
489 式(26) CO 式(a) 566.2
490 式(26) CO 式(b) 566.2
491 式(26) CO 式(c) 580.2
492 式(26) CO 式(d) 580.2
493 式(26) CO 式(e) 616.3
494 式(26) CO 式(f) 616.3
495 式(26) CO 式(g) 616.3
496 式(26) CO 式(h) 616.3
497 式(26) CO 式(i) 567.2
498 式(26) CO 式(j) 567.2
499 式(26) CO 式(k) 556.2
500 式(26) CO 式(l) 556.2
501 式(27) CO 式(a) 586.3
502 式(27) CO 式(b) 568.3
503 式(27) CO 式(c) 600.3
504 式(27) CO 式(d) 600.3
505 式(27) CO 式(e) 636.4
506 式(27) CO 式(f) 636.4
507 式(27) CO 式(g) 636.4
508 式(27) CO 式(h) 636.4
509 式(27) CO 式(i) 587.3
510 式(27) CO 式(j) 587.3
511 式(27) CO 式(k) 576.3
512 式(27) CO 式(l) 576.3
513 式(28) CO 式(a) 586.3
514 式(28) CO 式(b) 586.3
515 式(28) CO 式(c) 600.3
516 式(28) CO 式(d) 600.3
517 式(28) CO 式(e) 636.4
518 式(28) CO 式(f) 636.4
519 式(28) CO 式(g) 636.3
520 式(28) CO 式(h) 636.4
521 式(28) CO 式(i) 587.3
522 式(28) CO 式(j) 587.3
523 式(28) CO 式(k) 576.2
524 式(28) CO 式(l) 576.3
525 式(25) CO 式(m) 497.3
526 式(25) CO 式(n) 497.3
527 式(25) CO 式(o) 512.3
528 式(25) CO 式(p) 512.3
529 式(25) CO 式(q) 512.3
530 式(25) CO 式(r) 567.2
531 式(25) CO 式(s) 587.3
532 式(25) CO 式(t) 587.3
533 式(26) CO 式(m) 552.2
534 式(26) CO 式(n) 552.2
535 式(26) CO 式(p) 567.2
536 式(26) CO 式(q) 567.2
537 式(26) CO 式(r) 622.2
538 式(26) CO 式(s) 642.3
539 式(26) CO 式(t) 642.3
540 式(27) CO 式(m) 572.3
541 式(27) CO 式(n) 572.3
542 式(27) CO 式(o) 587.3
543 式(27) CO 式(p) 587.3
544 式(27) CO 式(q) 587.3
545 式(27) CO 式(r) 642.3
546 式(27) CO 式(s) 662.3
547 式(27) CO 式(t) 662.3
548 式(28) CO 式(m) 572.2
549 式(28) CO 式(n) 572.2
550 式(28) CO 式(o) 587.3
551 式(28) CO 式(p) 587.3
552 式(28) CO 式(q) 587.3
553 式(28) CO 式(r) 642.3
554 式(28) CO 式(s) 662.3
555 式(28) CO 式(t) 662.3
556 式(29) CO 式(u) *2
557 式(29) CO 式(w) *3
558 式(29) CO 式(x) *4
559 式(4) CO 式(u) *5
*1:ESIMS(Pos)
*2:HRMS(FAB)计算值C31H35N7O3 554.2880,实测值554.2908
*3:HRMS(FAB)计算值C33H39N7O3 582.3193,实测值582.3195
*4:HRMS(FAB)计算值C31H36N6O3 541.2927,实测值541.2955
*5:HRMS(FAB)计算值C40H41N7O3 668.3350,实测值668.3358
AR1-Y1-
式(1) 式(2) 式(3) 式(4) 式(5) 式(6)
式(70) 式(8) 式(9) 式(10) 式(11) 式(12)
式(13) 式(14) 式(15) 式(16) 式(17) 式(18)
式(19) 式(20) 式(21) 式(22) 式(23) 式(24)
式(25) 式(26) 式(27) 式(28) 式(29)
-Y2-Ar2 |
式(a) 式(b) 式(c) 式(d) 式(e) 式(f)
式(g) 式(h) 式(i) 式(j) 式(k) 式(l)
式(m) 式(n) 式(o) 式(p) 式(q) 式(r)
式(s) 式(t) 式(u) 式(v) 式(w)
式(x)
试验例[MC4受体结合实验]
MC4受体结合实验按照Pharmacology & Toxicology,79,161-165、1996中记载的方法进行。从Biolinks公司购入在HEK-293细胞中表达人MC4受体的人MC4受体表达细胞膜。将细胞膜在含有2mM乙二胺四乙酸、10mM氯化钙以及100μM苯基甲基磺酰氟的50mM三羟甲基氨基甲烷-盐酸缓冲液(pH7.4)中进行均化。均化物以48,000×g在4℃下离心分离20分钟。将离心分离得到的沉淀物用同样的缓冲液再次均化,将均化物在以48,000×g在4℃下离心分离20分钟。该操作重复2次。将沉淀物在含有2mM乙二胺四乙酸、10mM氯化钙、100μM苯基甲基磺酰氟以及0.1%牛血清白蛋白的50mM三羟甲基氨基甲烷-盐酸缓冲液(pH7.4)中混悬使蛋白质浓度为100μg/ml,作为粗膜标品用于结合实验。使粗膜标品(0.25ml、25μg蛋白质)与[125I]Nle4-D-Phe7-α-MSH(最终浓度为0.2nM)在25℃下反应120分钟。反应结束后,用受体结合实验用细胞收集器将反应液在GF/C玻璃纤维滤纸(在含有0.5%牛血清的20mM三羟甲基氨基甲烷-盐酸缓冲液(pH7.4)中浸泡过2小时)上抽滤。用γ计数器测定滤纸上的反射活性。以在1μM的Nle4-D-Phe7-α-MSH存在下的结合量作为非特异性结合,以1μM的Nle4-D-Phe7-α-MSH不存在下的结合作为总结合,从总结合中减去非特异性结合,得到的数值作为特异性结合。将被检药物溶于100%DMSO溶液中,与[125I]Nle4-D-Phe7-α-MSH同时添加至膜标品中。由10-9~10-5浓度的抑制曲线计算得出IC50值。
结果例如化合物224的IC50值为690nM。
式[1]表示的化合物或其医药上允许的盐,作为对MC4受体具有亲和性以及特异性的肽性配体有用,可以作为医药品使用。
Claims (6)
2.权利要求1记载的精氨酸衍生物或其医药上允许的盐,其中取代苯基是指被从C1-5烷基、C1-5烷氧基、芳烷氧基、羟基、卤素原子、硝基、氨基、单-C1-5烷基氨基、二-C1-5烷基氨基、三氟甲基以及苯基中任意选择的1~3个基团取代的苯基;取代萘基是指被从C1-5烷基、C1-5烷氧基、芳烷氧基、卤素原子、硝基、氨基、单-C1-5烷基氨基、二-C1-5烷基氨基、三氟甲基以及苯基中任意选择的1~3个基团取代的萘基;杂芳香环基是指含有一个以上氮、氧或硫原子的单环或2环芳香族环基。
3.权利要求1记载的精氨酸衍生物或其医药上允许的盐,其中Ar1以及Ar2可以相同或不同,表示苯基、萘基或3-苯并噻嗯基,Y1表示C1-2的亚烷基、或被1个乙酰氨基取代的C1-2亚烷基,Q表示羰基或磺酰基,Y2表示C1-2的亚烷基或被1个氨基甲酰基取代的C1-2亚烷基。
4.权利要求1记载的精氨酸衍生物或其医药上允许的盐,选自下列的a~n,
a.N2-[N-乙酰基-3-(2-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
b.N2-[N-乙酰基-3-(2-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
c.N2-[N-乙酰基-3-(2-萘基)-D-丙氨酰基]-N-[2-(2-萘基)乙基]-L-精氨酸酰胺
d.N2-[N-乙酰基-3-(1-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
e.N2-[N-乙酰基-3-(1-萘基)-D-丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
f.N2-[N-乙酰基-3-(1-萘基)-D-丙氨酰基]-L-精氨酰基-3-(1-萘基)-L-丙氨酸酰胺
g.N2-[N-乙酰基-D-苯基丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
h.N2-[N-乙酰基-D-苯基丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
i.N2-[N-乙酰基-D-苯基丙氨酰基]-N-[2-(2-萘基)乙基]-L-精氨酸酰胺
j.N2-[3-(2-萘基)丙酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
k.N2-[3-(1-萘基)丙酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
l.N2-[N-乙酰基-3-(3-苯并噻嗯基)-L-丙氨酰基]-L-精氨酰基-3-(2-萘基)-L-丙氨酸酰胺
m.N2-[N-乙酰基-3-(3-苯并噻嗯基)-L-丙氨酰基]-L-精氨酰基-3-(2-萘基)-D-丙氨酸酰胺
n.N2-[1-萘磺酰基]-L-精氨酰基-3-(3-苯并噻嗯基)-D-丙氨酸酰胺。
5.由权利要求1~4中任一项记载的精氨酸衍生物或其医药上允许的盐组成的药物。
6.权利要求1~4中任一项记载的精氨酸衍生物或其医药上允许的盐作为MC4受体配体的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP144659/2001 | 2001-05-15 | ||
JP2001144659 | 2001-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1535264A true CN1535264A (zh) | 2004-10-06 |
Family
ID=18990573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA028100948A Pending CN1535264A (zh) | 2001-05-15 | 2002-05-14 | 精氨酸衍生物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040147567A1 (zh) |
EP (1) | EP1388537A1 (zh) |
JP (1) | JP4010951B2 (zh) |
KR (1) | KR20040007565A (zh) |
CN (1) | CN1535264A (zh) |
CA (1) | CA2447314A1 (zh) |
WO (1) | WO2002092566A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
JP2005504043A (ja) * | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク. | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
AU2002330090A1 (en) * | 2001-09-24 | 2003-04-07 | Synaptic Pharmaceutical Corporation | Molecules specific for npff receptors and uses thereof |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US20100004339A1 (en) * | 2003-10-06 | 2010-01-07 | Oy Juvantia Pharma Ltd. | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists |
FI20031455A0 (fi) * | 2003-10-06 | 2003-10-06 | Juvantia Pharma Ltd Oy | Sulfonyyliamino-peptidomimeettejä, jotka ovat aktiivisia somatostatiinireseptorialatyyppien 4 (SSTR4) ja 1 (SSTR1) suhteen |
FI20031454A0 (fi) * | 2003-10-06 | 2003-10-06 | Juvantia Pharma Ltd Oy | Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
WO2007055873A2 (en) * | 2005-11-04 | 2007-05-18 | Avanir Pharmaceuticals | Process for the manufacture of peptide facilitators of reverse cholesterol transport |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
US8759539B2 (en) | 2008-11-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
GB0918579D0 (en) * | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9018395B2 (en) | 2011-01-27 | 2015-04-28 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
GB201613999D0 (en) | 2016-08-16 | 2016-09-28 | Neuro-Bio Ltd | Neurodegenerative disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL165652C (nl) * | 1973-08-13 | 1981-05-15 | Mitsubishi Chem Ind | Werkwijze ter bereiding van een preparaat met anti- trombosewerking en/of diagnosticum voor trombine in bloed op basis van l-argininederivaten, het gevormde preparaat, het gevormde diagnosticum en werkwijze ter bereiding van l-argininederivaten. |
US4069323A (en) * | 1974-11-08 | 1978-01-17 | Mitsubishi Chemical Industries Ltd. | N2 -substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof |
JPS5941991B2 (ja) * | 1975-08-08 | 1984-10-11 | 三菱化学株式会社 | N↑2−置換アルギニンアミド類またはその酸付加塩の製造法 |
JPS5198201A (en) * | 1975-02-18 | 1976-08-30 | n22 chikan omega amijino arufua aminosanjudotaimataha sonosanfukaenno seizoho | |
JPS5940146B2 (ja) * | 1975-08-13 | 1984-09-28 | 三菱化学株式会社 | N↑2−ナフタレンスルホニルアルギニンアミド類またはその酸付加塩の製造方法 |
JPS5825666B2 (ja) * | 1976-01-01 | 1983-05-28 | 三菱化学株式会社 | N↑2−置換−ω−アミジノ−α−アミノ酸誘導体またはその酸付加塩 |
JPS6010027B2 (ja) * | 1976-01-01 | 1985-03-14 | 三菱化学株式会社 | N↑2−ナフタレンスルホニル−l−アルギニン誘導体およびその酸付加塩 |
JPH0681722B2 (ja) * | 1984-02-06 | 1994-10-19 | 三菱化成株式会社 | 抗トリプシン剤 |
WO1994013692A1 (en) * | 1992-12-10 | 1994-06-23 | Regents Of The University Of Minnesota | Polypeptides useful for treating inflammatory disorders |
DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6030940A (en) * | 1995-07-31 | 2000-02-29 | Chiron Corporation | Peptide analog inhibitors of urokinase receptor activity |
US6114390A (en) * | 1995-11-30 | 2000-09-05 | Karl Thomae Gmbh | Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
DE19544687A1 (de) * | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
US20020012942A1 (en) * | 1998-01-22 | 2002-01-31 | Regents Of The University Of Minnesota | Polypeptides with a4 integrin subunit related activity |
-
2002
- 2002-05-14 WO PCT/JP2002/004666 patent/WO2002092566A1/ja not_active Application Discontinuation
- 2002-05-14 CN CNA028100948A patent/CN1535264A/zh active Pending
- 2002-05-14 US US10/477,736 patent/US20040147567A1/en not_active Abandoned
- 2002-05-14 EP EP02724787A patent/EP1388537A1/en not_active Withdrawn
- 2002-05-14 CA CA002447314A patent/CA2447314A1/en not_active Abandoned
- 2002-05-14 JP JP2002589452A patent/JP4010951B2/ja not_active Expired - Fee Related
- 2002-05-14 KR KR10-2003-7014843A patent/KR20040007565A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2447314A1 (en) | 2002-11-21 |
JP4010951B2 (ja) | 2007-11-21 |
EP1388537A1 (en) | 2004-02-11 |
KR20040007565A (ko) | 2004-01-24 |
US20040147567A1 (en) | 2004-07-29 |
JPWO2002092566A1 (ja) | 2004-08-26 |
WO2002092566A1 (fr) | 2002-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1535264A (zh) | 精氨酸衍生物 | |
CN1298703C (zh) | 氰基吡咯烷衍生物 | |
CN1207283C (zh) | 4-氨基哌啶衍生物和它们作为药物的用途 | |
CN1257891C (zh) | 含氮五员环化合物 | |
CN1224623C (zh) | 1-苯基磺酰基-1,3-二氢-2h-吲哚-2-酮衍生物,其制备及其治疗应用 | |
CN1192773C (zh) | 环胺ccr3拮抗剂 | |
CN1144791C (zh) | 三唑化合物及其作为多巴胺d3配体的应用 | |
CN1038939C (zh) | 肽类化合物的制备方法 | |
CN1298715C (zh) | 作为组胺h3拮抗剂的非咪唑化合物 | |
CN1260345A (zh) | 酰肼化合物、其制备方法及其药物组合物 | |
CN101050194A (zh) | 双环辛烷类衍生物、其制备方法及其在医药上的用途 | |
CN1780621A (zh) | 作为γ分泌酶抑制剂的磺酰胺衍生物 | |
CN1500081A (zh) | 乙内酰硫脲及其在治疗糖尿病方面的用途 | |
CN1107839A (zh) | 甲酰胺类化合物 | |
CN1867579A (zh) | 丙肝病毒的新的肽模拟物ns3-丝氨酸蛋白酶抑制剂 | |
CN1118595A (zh) | 氨茴酸衍生物 | |
CN1305493A (zh) | 新颖的环孢菌素 | |
CN1922139A (zh) | 双环酰胺衍生物 | |
CN101065376A (zh) | 2-酰胺基-4-苯基噻唑衍生物、它们的制备与治疗应用 | |
CN1065874C (zh) | 新的肽及其制备和应用 | |
CN1017707B (zh) | 新的噻唑化合物的制备方法 | |
CN1208318C (zh) | 环胺ccr5受体拮抗剂 | |
CN1516695A (zh) | 用作抗病毒剂的芳基磺酰胺类化合物 | |
CN1115337C (zh) | 嘧啶酮衍生物 | |
CN1571781A (zh) | 4-咪唑啉-2-酮化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1066976 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1066976 Country of ref document: HK |